Skip to content

Smith & Nephew Shares Trading In Range

Asktraders News Team trader
Updated 15 May 2025

Smith & Nephew shares (LON: SN) have been trading in a range for much of 2025, with the 1,000 level seemingly acting as a bit of a magnet for the stock. The company, a prominent FTSE 100 medical technology company, has seen shares gain 7.18% on a YTD basis, yet the resistance at 1,100 is proving a tough nut to crack.

Despite a move to the upside in early March, the stock struggled to hold on, with a reversal back to the 1,000 level testing support. With the stock failing to hold the level during the tariff induced sell-off, bulls were given a catalyst in recent financials that has once again given the shares some upside momentum.

The company reported a strong first quarter, achieving a 3.1% year-on-year revenue increase, reaching $1.407 billion, even as it faced challenges in the Chinese market.

The company is dealing with headwinds from China's Volume Based Procurement (VBP) system and tariffs in the United States, which are estimated to have a negative financial impact of $15 million to $20 million this year. Nonetheless, Smith & Nephew remains optimistic, forecasting an underlying revenue growth rate of approximately 5% by 2025. Analysts have projected that the company's earnings could rise by 16.6% annually through the end of 2027.

There is clearly some optimism in the analyst community that the company can continue to execute. With the street holding an average price target of 1,247, reflecting a perceived upside of more than 15%, a break above resistance that holds on heavy volume could help drive price action in the months to come.

Searching for the Perfect Broker?

Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!

YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY

Analysis Stocks Markets Strategies